RO1138452 is a selective antagonist of prostacyclin (IP) receptor with pKi of 9.3 ± 0.1 in human platelets.

Setipiprant is an orally available, selective CRTH2 antagonist.

DG-041 is a potent and selective antagonist of prostanoid EP3 receptor with IC50 of 4.6 nM.

Grapiprant is a selective EP4 receptor antagonist whose physiological ligand is prostaglandin E2 (PGE2).

L-798106 is a potent and highly selective prostanoid EP3 receptor antagonist (Ki values are 0.3, 916, > 5000 and > 5000 nM at EP3, EP4, EP1 and EP2, respectively), and it can attenuate sulprostone-induced inhibition of EFS-evoked twitch and contractile responses in vivo.

CJ-42794 is a selective prostaglandin E receptor subtype 4 (EP4) antagonist, inhibits [3H]-PGE2 binding to the human EP4 receptor with a mean pKi of 8.5, a binding affinity that was at least 200-fold selective for the human EP4 receptor than other human EP receptor subtypes (EP1, EP2, and EP3).

Asapiprant is a potent and selective DP1 receptor antagonist with a Ki of 0.44 nM.

OC000459 is a potent and selective D prostanoid receptor 2 (DP2) antagonist with IC50 of 13 nM.

Terutroban is a thromboxane/prostaglandin endoperoxide receptor antagonist.

Cloprostenol sodium salt (ICI 80996 sodium salt) is a potent synthetic prostaglandin analogue, acts as a luteolytic agent, and is a PGF2α receptor agonist.

GW627368 is a potent and selective competitive antagonist of prostanoid EP4 receptor (Ki= 100 nM) with additional human TP receptor affinity (Ki= 150 nM).

ONO-AE3-208 is an antagonist of EP4 with Ki of 1.3 nM and exhibits suppression the invasion and metastasis of prostate cancer cells.

Taprenepag is an agonist of prostaglandin E2 receptor with EC50 of 2.8 nM with hypotensive activity.

Licarin A, a natural product isolated and purified from Machilus thunbergii, is a candidate compound for the treatment of immediate hypersensitivity via inhibition of rat mast cell line RBL-2H3 cells.

NTP42 is a TxA2 Synthetase antagonist with IC50 value of 3.278nM.

NS-304 is an agonist of prostacyclin IP1 receptor with Ki of 260 nM. It is used for the treatment of pulmonary arterial hypertension.

Laropiprant is a potent, selective DP1 receptor antagonist with Ki value of 0.57 nM and exhibits > 1,000 fold selectivity over DP2 receptor (Ki=0.75 μM).

Treprostinil sodium is a potent DP1 and EP2 agonist with EC50 values of 0.6±0.1 and 6.2±1.2 nM, respectively.

Ramatroban is a thromboxane A(2) (TxA(2)) antagonist marketed for allergic rhinitis.